Moreover, patients with the KRASG12C mutation are typically subject to an immunosuppressive tumor microenvironment (TME) with a correlated increase in PD-L1 expression, and a decrease in the effectiveness of CD8+ due to downregulation of major histocompatibility complex (MHC) class I [5]. Here, CD274 is linked to neoplasm.